Objectives-Increased levels of IgA antibodies to cytokeratin-18 (CK-18) and epidermal keratins (EpK) in the sera of
There were no differences in the levels of IgG or IgM antibodies to or EpK between the patient groups and controls. Conclusions-Raised levels of IgA antibodies to CK-18 and EpK in psoriatic arthropathy and psoriasis probably reflect exposure of intracellular cytokeratin antigens to the immune system after damage to cytokeratin containing cells, and suggests a common pathogenic mechanism in these conditions which involves production of cytokeratin autoantibodies. In patients with psoriatic arthropathy, such a mechanism appears only to be operating in patients with peripheral joint involvement and not in those with axial arthritis.
(Ann Rheum Dis 1994; 53: [391] [392] [393] [394] [395] Cytokeratins are a constituent of the cytoskeleton, being found mainly in epithelial cells but also in some lymph node associated follicular dendritic cells and in certain endothelial and smooth muscle cells.' 2 There are at least 19 different cytokeratins comprised of two families; an acidic type (Type I, nos [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] and a basic or neutral type (Type II, nos 1-8). We and others2 3 have demonstrated CK-18 in the endothelial cells of synovial blood vessels, and have recently shown that IgA antibodies to CK-18 and EpK are raised in patients with RA. IgG and IgM antibodies to cytokeratins were not significantly different to the normal group. 4 We initially proposed that damage to synovial endothelial cells during inflammatory synovitis leads to the production of autoantibodies to CK-18.' However, our finding of a significant difference in IgA, but not IgG or IgM antibodies, may indicate that damage to cells in a mucosal site (for example, in the gut) is involved in the production of such antibodies, such as CK-18 and is one of the major cytokeratins found in the epithelial cells lining the gut. Further studies in our laboratory have shown high levels of these antibodies in patients with coeliac disease and inflammatory bowel disease (unpublished data).
An association between the spondyloarthropathies and abnormalities of the gut and mucosal immune system is well documented.5 6 We therefore carried out an investigation of anti-cytokeratin antibody levels in patients with AS, psoriatic arthritis, and in Reiter's syndrome. We also examined a group of patients with psoriasis for comparison with the spondyloarthropathies. In addition, we explored whether there are any associations between anti-cytokeratin antibodies and particular disease manifestations, and whether there are any correlations with serum IgA and laboratory measures of inflammation.
Patients and methods

PATIENTS
Serum specimens were obtained from 20 patients with AS, 42 patients with psoriatic arthropathy (skin involvement varied from mild to severe), 33 patients with severe psoriasis without any arthropathy, and 11 patients with Reiter's syndrome. The demographic data are shown in table 1. Sera was also obtained from 58 healthy control subjects consisting of department staff and blood donors. Local ethical committee approval was obtained for the collection of all samples.
All the patients with arthritis were negative for rheumatoid factor (Latex). The patients with psoriatic arthritis fulfilled the criteria of Moll and Wright,7 while the patients with AS fulfilled the 1966 New York Criteria.8 75% of the patients with psoriasis and 58% of the patients with psoriatic arthropathy. Raised levels of IgA antibodies to EpK were found in 83% of the patients with psoriasis and 50% of those with psoriatic arthropathy. There was no significant difference in the levels of IgG or IgM antibodies to CK-18 or EpK between the normal sera and those from the patient groups.
A significant correlation was found between the IgA antibody levels to CK-18 and EpK in the patients with psoriatic arthropathy (r = 0A43, p < 0 05), and in the patients with psoriasis alone (r = 0-65, p < 003). We found that serum IgA levels in psoriasis (mean = 5-55 mg/ml) and psoriatic arthropathy (mean = 5-26 mg/ml) were both significantly higher than in normal controls (mean = 2-4 mg/ml, p < 0-0001). There was, however, no correlation between serum IgA levels and IgA antibody levels to CK-18 or EpK in either group of patients.
We investigated whether there was any difference in the levels of IgA antibodies to There is no direct relationship between levels of IgA antibodies to cytokeratins and levels of serum IgA, even though all of the conditions studied, apart from Reiter's syndrome, are characterised by elevated levels of serum IgA. It has been proposed that elevated levels of serum IgA in patients with AS are related to stimulation of the mucosal compartment,'5 16 although a recent study has shown that the increase in IgA levels is not due to a significant increase in secretory IgA. '7 We have not investigated levels of secretory IgA in the sera of our patients with psoriasis and psoriatic arthropathy. It is possible that levels of IgA antibodies to cytokeratins are related to secretory IgA levels, but further studies are needed to address this question.
The possibility of a gut-related antigen source for generation of IgA antibodies to CK-
18 cannot be ruled out. Along with CK-8, CK-18 is the major cytokeratin in the epithelial cells of the gut, so any damage to these cells may lead to exposure of the intracellular CK-18 to cells of the immune system. The concept of dermatogenic enteropathy to link skin with gut disorders was introduced by Shuster and
Marks in 1965,18 although they later found that evidence of intestinal changes in small bowel biopsies from patients with psoriasis and eczema were non-specific and similar in controls. 19 However, Barry et a120 demonstrated that in patients with severe psoriasis, the jejunal mucosal architecture differed significantly from that in controls and suggested that the mucosal absorptive surface of the small bowel may be decreased. Furthermore, the concept of 'subclinical' bowel inflammation presenting with arthritis is well recognised. Simenon et al 6 with a combination of ileocolonoscopy and biopsy revealed subclinical inflammatory gut lesions in 67% of patients with unclassified seronegative spondyloarthropathies.
Other extra-articular features which occur in the spondyloarthropathies include uveitis, mouth ulcers and urethritis, all of which may involve damage to cytokeratin-containing tissues. If indeed such damage is responsible for increased production of IgA autoantibodies to CK-18, then such a mechanism would appear to occur only in patients with psoriatic arthropathy and peripheral joint disease, and not in those patients with spondylitis or Reiter's syndrome. Thus the grouping together of seronegative spondyloarthropathies on the basis of their negativity for IgM rheumatoid factor, the increased prevalence of HLA-B27 and their spectrum of clinical presentations, may mask some of the differences in their pathogenesis.
A We have no evidence at present that anticytokeratin antibodies are pathogenic. It has been suggested that the normal role of anticytokeratin antibodies is to eliminate cell breakdown products,30 so an increased production of such antibodies might be expected in response to pathological cell damage and/or increased cell turnover. In some conditions the tissue damage may be accompanied by a defect in immune function (for example, polyclonal B cell activation) leading to further enhancement of autoantibody production. It is clear that IgA anti-cytokeratin antibodies are not specific to a particular disease condition, and are most likely to represent an epiphenomenon in diseases such as psoriasis and psoriatic arthropathy. The absence of a significant cytokeratin response in psoriatic arthritis with spondylitis, and in AS and Reiter's syndrome, suggest that there are clear differences in the pathogenetic or immunogenetic mechanisms involved in these conditions. 
